Shed Tumor Cells Collected Via Lavage May Be Potential Diagnostic Tool

Share this content:
Tumor cells from ovarian neoplasms that are shed may be collected through lavage of the uterine cavity.
Tumor cells from ovarian neoplasms that are shed may be collected through lavage of the uterine cavity.

Tumor cells from ovarian neoplasms that are shed may be collected through lavage of the uterine cavity and subsequently used as a potential tool for early diagnosis of ovarian and endometrial cancer, according to a recent study published online ahead of print in the Journal of Clinical Oncology.1

Researchers led by Elisabeth Maritschnegg, PhD, of the Medical University of Vienna in Austria used the lavage of the uterine cavity in order to obtain samples from 65 patients, including 30 with ovarian cancer, 5 with endometrial cancer, 3 with other malignancies, and 27 with benign lesions that involved the gynecologic organs.

Samples were examined for any presence of somatic mutations through massively parallel sequencing as well as singleplex analysis.

The researchers were able to identify mutations, mainly in TP53, in 18 of 30 lavage samples in patients with ovarian cancer through massively parallel sequencing, and singleplex analysis of previously determined mutations was able to further identify 6 patients.

RELATED: Adjuvant Hormonal Therapy Is Safe in Epithelial Ovarian Cancer

Among these 24 patients, specific mutations could be identified, including one patient who was found to have occult ovarian cancer. All 5 of the patients with endometrial cancer were found to harbor mutations, and 8 of the 27 patients with benign lesions tested positive for mutations, with 6 of them from mutations in the KRAS gene.

“Detection of ovarian cancer and endometrial cancer and even clinically occult ovarian cancer was achieved, making it a potential tool of significant promise for early diagnosis,” the authors concluded.

Reference

  1. Maritschnegg E, Wang Y, Pecha N, et al. Lavage of the uterine cavity for molecular detection of Müllerian duct carcinomas: a proof-of-concept study [published online ahead of print November 9, 2015]. J Clin. Oncol. doi: 10.1200/JCO.2015.61.3083.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs